FMN2 is a novel regulator of the cyclin-dependent kinase inhibitor p21

被引:13
|
作者
Yamada, Kayo [1 ]
Ono, Motoharu [1 ]
Bensaddek, Dalila [1 ]
Lamond, Angus I. [1 ]
Rocha, Sonia [1 ]
机构
[1] Univ Dundee, Ctr Gene Regulat & Express, Coll Life Sci, Dundee, Scotland
基金
英国惠康基金;
关键词
DNA damage; FMN2; cancer; cell cycle; hypoxia; p14ARF; p21; p53; ARF TUMOR-SUPPRESSOR; NF-KAPPA-B; P53; TRANSACTIVATION; IDENTIFICATION; DEGRADATION; NETWORKS; REVEALS; CANCER; ATR;
D O I
10.4161/cc.25511
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
We have identified the human FMN2 gene as a novel target regulated by induction of p14ARF and by multiple other stress responses, including DNA damage and hypoxia, which have in common activation of cell cycle arrest. We showed that increased expression of the FMN2 gene following p14ARF induction is caused, at the transcriptional level, by relief of repression by RelA and E2F1, which, under non-induced conditions, bind the FMN2 promoter. Increased FMN2 protein levels promote cell cycle arrest by inhibiting the degradation of p21, and our data show that control of p21 stability is a key part of the mechanism that regulates p21 induction. Consistent with this model, we have shown that transient expression of exogenous FMN2 protein alone is sufficient to increase p21 protein levels in cells, without altering p21 mRNA levels. Here, we provide additional evidence for the role of the N terminus of FMN2 as being the important domain required for p21 stability. In addition, we also investigate the role of RelA's threonine 505 residue in the control of FMN2. Our results identify FMN2 as a crucial protein involved in the control of p21.
引用
收藏
页码:2348 / 2354
页数:7
相关论文
共 50 条
  • [31] Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias
    Gojo, Ivana
    Sadowska, Mariola
    Walker, Alison
    Feldman, Eric J.
    Iyer, Swaminathan Padmanabhan
    Baer, Maria R.
    Sausville, Edward A.
    Lapidus, Rena G.
    Zhang, Da
    Zhu, Yali
    Jou, Ying-Ming
    Poon, Jennifer
    Small, Karen
    Bannerji, Rajat
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (04) : 897 - 908
  • [32] Topographical association between the cyclin-dependent kinases inhibitor P21, p53 accumulation, and cellular proliferation in human atherosclerotic tissue
    Ihling, C
    Menzel, G
    Wellens, E
    Monting, JS
    Schaefer, HE
    Zeiher, AM
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (10) : 2218 - 2224
  • [33] Role of c-myc regulation in Zta-mediated induction of the cyclin-dependent kinase inhibitors p21 and p27 and cell growth arrest
    Rodriguez, A
    Jung, EJ
    Yin, QY
    Cayrol, C
    Flemington, EK
    VIROLOGY, 2001, 284 (02) : 159 - 169
  • [34] A naturally occurring mixture of tocotrienols inhibits the growth of human prostate tumor, associated with epigenetic modifications of cyclin-dependent kinase inhibitors p21 and p27
    Huang, Ying
    Wu, Renyi
    Su, Zheng-Yuan
    Guo, Yue
    Zheng, Xi
    Yang, Chung S.
    Kong, Ah-Ng
    JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2017, 40 : 155 - 163
  • [35] Discovery of novel macrocyclic derivatives as potent and selective cyclin-dependent kinase 2 inhibitors
    Niu, Pengpeng
    Tao, Yanxin
    Meng, Qingyuan
    Huang, Yixing
    Li, Shan
    Ding, Ke
    Ma, Dawei
    Ye, Zu
    Fan, Mengyang
    BIOORGANIC & MEDICINAL CHEMISTRY, 2024, 104
  • [36] Evidence for a differential modulation of p53-phosphorylating kinases by the cyclin-dependent kinase inhibitor p21WAF1/CIP1
    Neise, Denise
    Sohn, Dennis
    Budach, Wilfried
    Jaenicke, Reiner U.
    CELL CYCLE, 2010, 9 (17) : 3575 - 3583
  • [37] Drug Design of Cyclin-Dependent Kinase 2 Inhibitor for Melanoma from Traditional Chinese Medicine
    Tang, Hsin-Chieh
    Chen, Calvin Yu-Chian
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [38] Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21
    Cayrol, C
    Ducommun, B
    ONCOGENE, 1998, 17 (19) : 2437 - 2444
  • [39] Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21
    Corinne Cayrol
    Bernard Ducommun
    Oncogene, 1998, 17 : 2437 - 2444
  • [40] Identification of the region required for the antiapoptotic function of the cyclin kinase inhibitor, p21
    Nakamura, K
    Arai, D
    Fukuchi, K
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2004, 431 (01) : 47 - 54